Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Gilead Sciences Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale increased by 56.5% to $36.00M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale shows a downward trend with a -70.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher inflows provide liquidity for reinvestment, though they may signal a need to reinvest in a potentially different interest rate environment.
Detailed definition
Captures the cash inflows from the scheduled maturity, early prepayment, or issuer-called redemption of debt securities...
Peer comparison
Standard for insurance companies and banks with significant bond portfolios.
other_proceeds_from_maturities_prepayments_and_calls_of__434faeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $631.00M | $558.00M | $372.00M | $506.00M | $449.00M | $277.00M | $358.00M | $324.00M | $395.00M | $266.00M | $349.00M | $327.00M | $0.00 | $15.00M | $17.00M | $23.00M | $36.00M |
| QoQ Change | — | -11.6% | -33.3% | +36.0% | -11.3% | -38.3% | +29.2% | -9.5% | +21.9% | -32.7% | +31.2% | -6.3% | -100.0% | — | +13.3% | +35.3% | +56.5% |
| YoY Change | — | — | — | — | -28.8% | -50.4% | -3.8% | -36.0% | -12.0% | -4.0% | -2.5% | +0.9% | -100.0% | — | — | — | — |
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Gilead Sciences (GILD) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $36.00M in Q1 2026.
- What is the long-term trend for Gilead Sciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 3 years (2021 to 2025), Gilead Sciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a -70.7% compound annual growth rate (CAGR), from $2.18B to $55.00M.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- Cash received from debt securities that have matured, been prepaid, or were called by the issuer.